ROCKVILLE, MD — August 22, 2024 — The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) announced today the open comment period for the revised 2018 evidence-based guideline, "Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors."
"Rapid advancements in adjuvant and neoadjuvant therapy for patients with early-stage non-small cell lung carcinoma make this revision essential to guide optimal patient care," said guideline update co-chair Sinchita Roy-Chowdhuri, MD, PhD, FCAP, Professor of Pathology at The University of Texas MD Anderson Cancer Center. "This revised guideline provides a clear framework based on evidence from recently published clinical literature."
